Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, we can support you in therapeutic areas such as immuno-oncology, inflammation and infectious diseases. To get the right expert to best answer you, please tell us exactly what you need. We will do everything we can to make your project a joint success.
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260